PATENT CLAIM ANALYSIS

Application Number: 15991326
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-02
Patent Classification: ["514", "04400A"]

Abstract:
The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.

Claim (Index 13):
The antisense oligonucleotide according to any one of  claims 1 - 12 , wherein the internucleoside linkages between the nucleotides of the contiguous nucleotide region are all phosphorothioate internucleotides linkages.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 93.0
- Lexical Diversity: 1.4
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15635629', '15971951', '14897223', '15971970', '15836144']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7752654659686843
- 35 USC 102 Novelty (BERT): 0.6198634626224638
- Combined Prediction Score: 0.7597252656340623
- Mean Citation Score: 424.386488
- Max Citation Score: 602.95087
- Similarity Product: 479.47547468824206

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test